Medblocs
Early Stage
Accelerate Clinical Trials Using AI
Analytics
Raised: $3,020
Aggregate Commitments $
Platform
StartEngine
Start Date
12/18/2018
Close Date
03/14/2019
Min. Goal
$10,000
Max. Goal
$107,000
Min. Investment
$200
Security Type
Equity - Common
Funding Type
RegCF
Price Per Share
$0.12
Pre-Money Valuation
$1,100,000
Rolling Commitments $
Status
Not Funded
Reporting Date
03/13/2019
Days Remaining
Not Funded
% of Min. Goal
30%
% of Max. Goal
3%
Likelihood of Max
Not Funded
Avg. Daily Raise
$35
# of Investors
10
Momentum
Not Funded
Create a free account today to gain access to KingsCrowd analytics.
Location
Cary, North Carolina
Industry
Healthcare & Pharmaceuticals
Tech Sector
Medblocs is an innovative startup that provides artificial intelligence (AI) solutions to accelerate clinical trials, blockchain solutions to share important clinical data, and a one-stop consumer app called YourHealthWallet. Medblocs is backed by a growing international team with extensive experience in the pharma and clinical trial industries. Our mission is to revolutionize and accelerate the current processes so that anyone in the world can gain easier access to research drugs and participate in trials.
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.